**Supplementary Material**

**Genetic association studies of fibromuscular dysplasia identify new risk loci and shared genetic basis with more common vascular diseases**

Georges et al.

**METHODS**

**Description of case-control studies**

**ARCADIA**

FMD patients were included from the ARCADIA (Assessment of Renal and Cervical Artery DysplasIA) register, a national FMD registry at the Georges Pompidou European Hospital, APHP, Paris1. The diagnosis of FMD was established using clinical information from the medical history, the interpretation of angiography and/or computed tomography scan of arterial beds after the exclusion of other causes of arterial stenosis such as atherosclerosis, Takayasu disease, Ehlers Danlos syndrome and neurofibromatosis type 1. Given the complexity of the interpretation of imaging of vascular diseases, a local panel of experts including clinicians from the departments of hypertension, radiology, vascular medicine and medical genetics validated the diagnosis. ARCADIA/PROFILE protocol was approved by the Ile-De-France research ethics committee (Comité de Protection des Personnes: CPP d’île de France) on 03/04/2009 (ID: 2009-A00288-49).

**Three City (3C)**

The Three-City Study (3C Study) is a population-based longitudinal study of the relation between vascular diseases and dementia in persons aged 65 years and older2. Participants were recruited from three French cities: Bordeaux (South-West), Dijon (North-East) and Montpellier (South-East). The 3C Study extended from 1999 to 2012. Participants underwent regular extensive examination. Examination included measurements of traditional vascular risk factors (blood pressure, glycaemia, lipids, etc.), cognitive functions, and subclinical vascular diseases using carotid ultrasound and cerebral magnetic-resonance imaging (MRI). The study protocol was approved by “comité consultatif de protection des personnes dans la recherche biomédicale Bicêtre Hôpital Bicêtre n°99-28 CCPPRB approved 10/06/99, 11/03/2003 and 17/03/2006.

**Mayo VDB Case-Control study**

Potential FMD cases and controls were identified from the Mayo Vascular diseases Biorepository (VDB)3. Electronic health records of 209 patients were manually reviewed by clinicians and the diagnosis was confirmed for 175 patients according to previously reported criteria4, of whom 169 (83.4% females) had high-density genotyping data following QC. Controls (n=1141) were participants without known FMD or atherosclerotic vascular diseases. The study was approved by the Mayo Clinic Institutional Review Boards (IRB # 08–008355).

**DEFINE-FMD Study.**

Eligible cases were females with an imaging-confirmed diagnosis of multifocal FMD and who fulfilled other accepted diagnostic criteria4,5. Healthy controls were matched to FMD cases according to age and sex, required to be receiving ≤ 2 blood pressure medications, have a body mass index < 35kg/m2 and to be non-smokers. Healthy controls underwent physical exam and those with bruits; unexplained hypertension or other cardiovascular findings were excluded. Exclusion criteria for all subjects included male gender, unifocal FMD, use of immunosuppressive agents, major comorbidities, diseases that may confound genetic/genomic analyses (i.e. Crohn’s disease, multiple sclerosis etc.) or any other form of heritable vascular disease (i.e. Ehlers-Danlos, Marfan, Loeys-Dietz)5. DEFINE-FMD study was approved by the Human Research Ethics Committee of the Icahn School of Medicine at Mount Sinai (Study ID: HS#13-00575/GCO#13–1118 and is registered with ClinicalTrials.gov Identifier: NCT01967511.

**ARCADIA-POL**

Patients were recruited through the ARCADIA-POL (Assessment of Renal and Cervical Artery Dysplasia - POLAND) study, a nation-wide Polish registry for FMD6. From January 2015 until December 2018, 343 patients, women and men aged more than 18 years were referred from 32 centers in Poland and were evaluated for suspicion of FMD in the Institute of Cardiology, Warsaw, Poland. FMD lesions in at least one vascular bed were confirmed in 232 patients using whole-body angio-computed tomography. We analysed 129 patients for whom we excluded atherosclerotic stenosis and syndromes where FMD-like lesions are often observed (eg, Ehlers Danlos, Loeys-Dietz). ARCADIA-Pol study was approved by Local Ethics Comittee, Institute of Cardiology, IK-NPIA-0021017/1482/17.

**WOBASZII**

We used 298 controls from a randomly ascertained sample from the WOBASZ II (Multicentre National Population Health Examination Survey) study, a population-based Polish cohort7. The WOBASZ II study was planned as a cross-sectional survey of a random sample of Polish residents aged over 20 years. The selection, using the National Identity Card Registry of the Ministry of Internal Affairs, was made as a three-stage sampling, stratified according to administrative units (voivodeships), type of urbanisation (commune), and gender. The study protocol consisted of a questionnaire used in face-to-face interviews, physical examination, and blood samples. WOBASZ II was coordinated by the Department of Epidemiology, Cardiovascular Diseases Prevention and Health Promotion of the Institute of Cardiology in Warsaw in cooperation with medical universities in Gdansk, Katowice, Krakow, Lodz, and Poznan. The study was accepted by the Field Bioethics Committee of the Institute of Cardiology in Warsaw.

**University of Michigan/Cleveland Clinic case control study**

FMD patients were recruited at the University of Michigan (UM) and/or the Cleveland Clinic. UM FMD cases were recruited into an IRB-approved study through a referral clinic at the University of Michigan and through self-referral to the study. The Cleveland Clinic cases were enrolled among consecutive patients seen at a dedicated FMD referral clinic. Clinical diagnosis of FMD was ascertained by a vascular medicine specialist after review of diagnostic imaging and prior to blood sample collection. DNAs from healthy controls without vascular disease were obtained from the Cleveland Clinic GeneBank, which was approved by the Cleveland Clinic IRB. Genomic DNA was isolated from a peripheral blood or saliva sample. The Michigan Genomics Initiative (MGI) is a program that recruited participants while awaiting diagnostic, interventional, and surgical procedures. Participants provided a blood sample for genetic analysis and agreed to link their sample to their electronic health record and other sources of health information8. Several ICD codes corresponding to diagnoses of arterial aneurysm, dissection, and non-atherosclerotic dysplasia and stenosis were excluded, as well as connective tissue disorders, as previously described9. The hypertension variable was defined as any ICD code containing the “hypertension” term for MGI controls. The UM/Cleveland case control study was approved by each institution IRB protocols: The University of Michigan IRB number HUM00044507 and the Cleveland Clinic IRB number 10–318.

**FMD European/International Registry and Initiative (FEIRI)**

Patients were enrolled through the European/International FMD Registry and Initiative (FEIRI)10. FMD was defined as the presence of an idiopathic, segmental, nonatherosclerotic, and noninflammatory stenosis (either with focal or string-of-beads appearance) of a small- or medium-sized artery in at least 1 vascular bed, documented with computed tomographic angiography, magnetic resonance angiography, or catheter-based angiography imaging. Patients with a suspicion of FMD only based on duplex ultrasound were excluded. Patients whose primary diagnosis was spontaneous coronary artery dissection were not eligible, even in the presence of extracoronary FMD lesions. Data on demographic and FMD characteristics were collected through the FMD Registry. All centres included in FEIRI received approval from the respective local/ national ethics committees.

**ASKLEPIOS**

The Asklepios Study is a longitudinal population study focusing on the interplay between ageing, cardiovascular haemodynamics and inflammation in preclinical cardiovascular disease11. Participants aged 35 to 55 years were sampled from the twinned Belgian communities of Erpe-Mere and Nieuwerkerken. Exclusion criteria were the presence of atherosclerotic lesions and concomitance with major illness, diabetes or conditions precluding accurate haemodynamic assessment. All participants underwent systematic physical examination during a continuous 2-year period, between October 2002 and September 2004 at a single study site in Erpe–Mere involving: measurement of basic clinical data, blood samples collection, echocardiographic examination and vascular echography and tonometric measurements. The ethical committee of the Ghent University Hospital approved the study protocol.

**Array-based genotyping, imputation and expression quantitative trait loci analysis**

Genotyping data quality control was performed using PLINK v 2.022 . We checked for sex mismatches, first degree relatedness and ancestry estimation. Genotyping data were filtered using the criteria of Hardy-Weinberg equilibrium exact test p value smaller than 0.001 (--hwe 0.001, default value in PLINK 2.0) and missingness per marker >1% (--geno 0.01). The minimum allele frequency was set to 0.01 (--maf 0.01). Data was imputed using minimac4 incorporated in a cloud-based imputation server using HRC r1.1 2016 reference panel23. R package Matrix eQTL v.2.1.1 was used to compute *cis*- regulated expression quantitative trait loci (eQTLs) in the cohorts of cases, controls and cases plus controls respectively24. Age and the first five genetics principal components were applied as covariates. Case control status was accounted as a covariate effect for the case-control pooled cohort. All cis-regulatory SNPs were located within 1Mb of the gene by using the hg19 genome (Ensembl Gene annotation build 75) and statistics were calculated by a linear model.

**Assay for transposase accessible chromatin (ATAC-Seq)**

Primary cells at passage 5 or 6 were trypsinized, counted using a Nucleocounter NC-100 (Chemometec, Allerod, Denmark), and 50,000 cells were collected for each experiment. The transposition reaction was performed as described in the Omni-ATAC protocol12. Then, the transposition reaction was purified with MinElute PCR Purification Kit (QIAGEN, Hilden, Germany). Library amplification was performed as described previously.13 Amplified DNA was purified using Agencourt AMPure XP beads (Beckman Coulter, Brea, CA), according to manufacturer’s instructions. Tagmented fragments were isolated and PCR-amplified for 6-9 cycles as described previously12. ATAC-seq libraries were sequenced using 42 paired-end sequencing cycles on an Illumina NextSeq500 system at the high throughput sequencing core facility of Institute for Integrative Biology of the Cell (CNRS, France, Centre de Recherche de Gif – http://www.i2bc.paris-saclay.fr/). Reads were demultiplexed using bcl2fastq2-2.18.12, and 31 to 95 million reads (fragments) were obtained per sample. Adapter sequences were trimmed using CutAdapt v1.15. Raw reads from healthy coronary artery samples were retrieved from sequence read archive (SRR2378591, SRR2378592, SRR2378593).

Analyses were performed on the Galaxy webserver.14 Reads were mapped on GRCh38 (hg38) genome using Bowtie2 v2.3.4.3 with default settings, except reads could be paired at up to 2kb distance. Aligned reads were filtered using BAM filter v0.5.9, keeping only mapped, properly paired reads, and removing secondary alignment and PCR duplicate reads as well as blacklisted regions.15 ATAC peaks were called using MACS2 callpeak v2.1.1.20160309.6 with default settings. Binary read density files (bigwig) were created using bamCoverage v3.3.0.0.0, normalized on hg38 genome.

To perform sample correlation and principal component analyses, a common list of enriched regions was generated using bedtools multiple intersect (Galaxy Version 2.29.0) in “cluster” mode, and average read coverage on these regions was computed using deepTools multiBamsummary (Galaxy Version 3.3.2.0.0). deepTools plotCoverage and plotPCA functions were used to calculate Spearman correlation between samples and Principal Component Analysis, respectively. Global peak annotation was performed using ChIPSeeker v1.22.0.16 We used Diffbind (Galaxy Version 2.10.0) to detect differentially accessible regions between Artery and SMC and Artery and EC samples.17 Peaks enriched in arteries in both conditions were taken as artery specific peaks (N = 5251). clusterProfiler v3.14.0 was used to annotate genes at proximity (≤10kb, 1425 genes) of ATAC-Seq peaks and identify enriched gene ontology terms.18 Identified GOBP terms were clustered using REVIGO webserver (<http://revigo.irb.hr/>), with “medium” settings.19We used DAVID webserver (<https://david.ncifcrf.gov/>) to perform functional annotation clustering with default parameters except GO FAT categories were added to the analysis.

**Whole transcriptome sequencing of primary dermal fibroblasts**

Whole transcriptome sequencing for primary fibroblast cell lines from the DEFINE-FMD study was performed on an Illumina HiSeq2000 using single end 100 base pair library preparation. Quality control was performed using FASTQC ([www.bioinformatics.babraham.ac.uk/projects/fastqc/](http://www.bioinformatics.babraham.ac.uk/projects/fastqc/)) that checks raw sequence data for per-base quality, per-sequence quality, number of duplicate reads, number of reads with an adaptor, sequence length distribution, per-base GC content, per-sequence GC content and Kmer content. GENCODE 29 was used as reference annotation to quantify gene and long non-coding RNA (lncRNA) expression. Sequencing reads (fastq files) were mapped to GRCh38 human reference genome using STAR aligner (version 3.6.0c) with default mapping parameters20. Low counts were removed by keeping genes where the count per million (cpm) is greater than 1 in at least two samples. After filtering zero and low counts, an average of 34 million reads were retained per sample. Primary FMD fibroblast RNA sequencing was performed as two cohorts, both with balanced numbers of cases and controls, and data were merged for subsequent analysis. Differential gene expression was analyzed by R (3.5.1) package sva21 and batch was adjusted as the covariate in linear regression model. Statistical significance was defined as combat p < 0.05.

**SUPPLEMENTARY FIGURE LEGENDS**

**Figure S1. Gene-based and transcriptome wide association analyses**

**a-c:** Quantile-quantile plot representation of SNP-based association analysis in: **a:** all FMD cases study. **b:** Multifocal FMD study. **c:** Women FMD study. -log10 of observed association *P*-value is represented on the y-axis, expected *P*-value on the x-axis. Genomic control value (λGC) is indicated over the graph for each study.

**d-e:** Manhattan plot representation of: **d:** SNP-based association analysis in all FMD cases. **e**: SNP-based association analysis in women FMD cases versus women controls. -log10 of association *P*-value is represented on the y-axis, genomic coordinates on the x-axis. Name of lead SNPs with *P*-value ≤ 5**×**10-8 are indicated.

**Figure S2. rs9349379-PHACTR1 eQTL in primary fibroblasts**

Boxplot representation of *PHACTR1* normalized expression with respect to rs9349379 genotype in primary fibroblasts. **a**: FMD cases and controls. **b:** FMD patients only. **c**: Controls only.eQTL *P*-value is indicated.

**Figure S3. FMD-eQTL colocalization at *ATP1B1* and *LIMA1* loci**

Colocalization plot of FMD association (x-axis, log scale of *P*-value) with arterial eQTL association (y-axis, log-scale of *P*-value) at *ATP2B1* (**a**: *ATP2B1-AS1*) and *LIMA1* (**b**: *COX14*, **c**: *LIMA1*, **d**: *SMARCD1*) loci. Dot color represents the LD r2 with the lead variant in 1000G European samples. FMD lead variant is highlighted (purple diamond). Approximate Bayes Factor Posterior Probability (*PP.abf*) for the two traits to share a common causal variant is indicated.

**Figure S4. FMD association and eQTLs at *SLC24A3* locus**

**a-b**: LocusZoom representation of FMD association signal at proximity of *SLC24A3* locus. Dot color indicates linkage disequilibrium of each variant with the highlighted lead variant (purple diamond). **a**: rs6046121. **b**: rs2424245. **c-e**: Violin plots representing normalized expression of *SLC24A3* in artery tissue by genotype of variant. **c**: rs6046121 in tibial artery. **d**: rs6046121 in aorta. **e**: rs2424245 in tibial artery. eQTL *P*-value is indicated.

**Figure S5. Comparison of FMD TWAS analyses in multifocal and women FMD**

**a-c:** Manhattan plot representation of transcriptome-wide association analysis in multifocal FMD (**a**) and women FMD (**c**) with tibial artery gene expression models. -log10 of association *P*-value is represented on the y-axis, genomic coordinates on the x-axis. Name of genes with Bonferroni corrected *P*-value ≤0.05 are indicated. **b-d**: Volcano plot representation of TWAS. **b**: Multifocal FMD. **d**: Women FMD. TWAS Z-score is represented on the x-axis, -log10 of TWAS *P*-Value on the y-axis. Dashed line represents the threshold for significance adjusted for multiple testing. Name of genes with FDR ≤ 0.05 are indicated.

**Figure S6. Single-cell expression of FMD associated genes in mouse aorta**

Violin plot representation of the expression of FMD associated genes in the single cell analysis of mouse aorta tissue by Kalluri and colleagues25. Unsupervised graph clustering was used to generate cell clusters, which were attributed to cell types according to the expression of canonical markers such as SMC markers *Myh11*, *Acta2 or Tagln.* Single-cell data were accessed and graphs were generated through Broad institute single cell portal (<https://singlecell.broadinstitute.org/single_cell>). **a**: *Phactr1*, **b**: *Lrp1*, **c**: *Atp2b1*, **d**: *Atf1*, **e**: *Lima1*, **f**: *Slc24a3*, **g**: *Stat6*. Query for *Gpd1* retrieved no results.

**Figure S7. Gene expression of FMD associated genes in tibial artery tissue.**

Box-plot representation of the expression (in tags-per-million, y-axis, log scale) of FMD associated genes (x-axis) in the 663 tibial artery samples from GTEx database.

**Figure S8. Sex-specific expression of FMD associated genes in tibial artery tissue.**

Violin-plot representation of the expression (in tags-per-million, y-axis, log scale) of FMD associated genes (x-axis) in the female (F, N = 209) and male (M, N = 454) tibial artery samples from GTEx database. Student’s t-test *P*-value is indicated on the graph.

**Figure S9. Expression of FMD associated genes in patient-derived fibroblasts.**

Bar plot representation of the normalized expression of top FMD associated genes (**A**: *PHACTR1*, **B**: *LRP1*, **C**: *ATP2B1*, **D**: *ATF1*, **E**: *LIMA1*, **F**: *SLC24A3*) in dermal fibroblasts derived from FMD patients (N = 83) and matched control patients (N = 70). Differential gene expression *P*-value is indicated above the graph. Error bars represent the standard error of the mean.

**Figure S10. Colocalization of FMD association with other vascular traits and diseases**

Colocalization plot of FMD association (x-axis, log scale of *P*-value) with pulse pressure, systolic blood pressure, migraine, cervical artery dissection, and coronary artery disease association (y-axis, log-scale of *P*-value) at *PHACTR1*, *LRP1*, *ATP2B1*, *LIMA1* and *SLC24A3* loci. Dot color represents the LD r2 with the lead variant in 1000G European samples. Best candidate variant for colocalization is highlighted (purple diamond). Red stars indicate the loci with at least one FMD associated variant with suggestive association (*P* ≤ 10-5) for the second trait.

**REFERENCES**

1. Plouin, P.F. *et al.* High Prevalence of Multiple Arterial Bed Lesions in Patients With Fibromuscular Dysplasia: The ARCADIA Registry (Assessment of Renal and Cervical Artery Dysplasia). *Hypertension* **70**, 652-658 (2017).

2. Vascular factors and risk of dementia: design of the Three-City Study and baseline characteristics of the study population. *Neuroepidemiology* **22**, 316-25 (2003).

3. Ye, Z., Kalloo, F.S., Dalenberg, A.K. & Kullo, I.J. An electronic medical record-linked biorepository to identify novel biomarkers for atherosclerotic cardiovascular disease. *Glob Cardiol Sci Pract* **2013**, 82-90 (2013).

4. Gornik, H.L. *et al.* First International Consensus on the diagnosis and management of fibromuscular dysplasia. *Vasc Med* **24**, 164-189 (2019).

5. Olin, J.W. *et al.* A Plasma Proteogenomic Signature for Fibromuscular Dysplasia. *Cardiovasc Res* (2019).

6. Dobrowolski, P. *et al.* Echocardiographic assessment of left ventricular morphology and function in patients with fibromuscular dysplasia: the ARCADIA-POL study. *J Hypertens* **36**, 1318-1325 (2018).

7. Drygas, W. *et al.* Multi-centre National Population Health Examination Survey (WOBASZ II study): assumptions, methods, and implementation. *Kardiol Pol* **74**, 681-90 (2016).

8. Fritsche, L.G. *et al.* Association of Polygenic Risk Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan Genomics Initiative. *Am J Hum Genet* **102**, 1048-1061 (2018).

9. Saw, J. *et al.* Chromosome 1q21.2 and additional loci influence risk of spontaneous coronary artery dissection and myocardial infarction. *Nat Commun* **11**, 4432 (2020).

10. Pappaccogli, M. *et al.* THE EUROPEAN/INTERNATIONAL FIBROMUSCULAR DYSPLASIA REGISTRY AND INITIATIVE (FEIRI)- CLINICAL PHENOTYPES AND THEIR PREDICTORS BASED ON A COHORT OF ONE THOUSAND PATIENTS. *Cardiovasc Res* (2020).

11. Rietzschel, E.R. *et al.* Rationale, design, methods and baseline characteristics of the Asklepios Study. *Eur J Cardiovasc Prev Rehabil* **14**, 179-91 (2007).

12. Corces, M.R. *et al.* An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. *Nat Methods* **14**, 959-962 (2017).

13. Buenrostro, J.D., Wu, B., Chang, H.Y. & Greenleaf, W.J. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. *Curr Protoc Mol Biol* **109**, 21 29 1-21 29 9 (2015).

14. Afgan, E. *et al.* The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic Acids Res* **46**, W537-W544 (2018).

15. Amemiya, H.M., Kundaje, A. & Boyle, A.P. The ENCODE Blacklist: Identification of Problematic Regions of the Genome. *Sci Rep* **9**, 9354 (2019).

16. Yu, G., Wang, L.G. & He, Q.Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. *Bioinformatics* **31**, 2382-3 (2015).

17. Ross-Innes, C.S. *et al.* Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. *Nature* **481**, 389-93 (2012).

18. Yu, G., Wang, L.G., Han, Y. & He, Q.Y. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* **16**, 284-7 (2012).

19. Supek, F., Bosnjak, M., Skunca, N. & Smuc, T. REVIGO summarizes and visualizes long lists of gene ontology terms. *PLoS One* **6**, e21800 (2011).

20. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21 (2013).

21. Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E. & Storey, J.D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* **28**, 882-3 (2012).

22. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, 7 (2015).

23. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284-1287 (2016).

24. Shabalin, A.A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. *Bioinformatics* **28**, 1353-8 (2012).

25. Kalluri, A.S. *et al.* Single-Cell Analysis of the Normal Mouse Aorta Reveals Functionally Distinct Endothelial Cell Populations. *Circulation* **140**, 147-163 (2019).

**Investigators of the European/International FMD Registry and Initiative (FEIRI)**

**who contributed to this study.**

*Belgium*: Alexandre Persu, Marco Pappaccogli, Christophe Beauloye, Patrick Chenu, Frank Hammer, Pierre Goffette, Parla Astarci, André Peeters, Robert Verhelst and Miikka Vikkula (Cliniques Universitaires Saint-Luc, Brussels); Patricia Van der Niepen and Frank Van Tussenbroek (Universitair Ziekenhuis Brussel, Brussels); Tine De Backer, Sofie Gevaert, Dimitri Hemelsoet and Luc Defreyne (Universitair Ziekenhuis Gent, Gent); Hilde Heuten, Laetitia Yperzeele and Thijs Van der Zijden (Universitair Ziekenhuis Antwerpen, Antwerpen); Jean-Philippe Lengelé (Grand Hôpital De Charleroi, Charleroi); Jean-Marie Krzesinski and Muriel Sprynger (CHU Sart-Tilman, Liège); Philippe Delmotte (Hopitâl Ambroise Paré, Mons); Peter Verhamme and Thomas Vanassche (UZ-Gasthuisberg, Leuven); Pasquale Scoppettuolo and Jean-Claude Wautrecht (University Hospital ULB Erasme, Brussels, Belgium);Wouter Vinck (GZA ziekenhuizen – campus Sint-Augustinus, Wilrijk).

*Croatia*: Bojan Jelaković and Zivka Dika (Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, School of Medicine University of Zagreb, Zagreb, Croatia)

*Finland*: Daniel Gordin, Ilkka Tikkanen, Maarit Venermo and RN Anita Mäkelä (Helsinki University Hospital, Helsinki, Finland)

*France*: Laurent Toubiana (FEIRI platform- Sorbonne Université, Université Paris 6, Sorbonne Paris Cité, INSERM, UMR\_S1142, LIMICS ; IRSAN Research Institute for the valorization of health data, Paris, France).

*Germany*: Felix Mahfoud, Juliane Dederer and Saarraaken Kulenthiran (Saarland University Hospital, Homburg/Saar)

*Ireland*: Caitriona Canning (St. James’s Hospital, Dublin, Ireland)

*Italy:* Rosa Maria Bruno, Stefano Taddei and Alessandra Bacca (Department of Clinical and Experimental Medicine University of Pisa, Pisa), Ilaria Petrucci (Sant’Anna School of Advanced Studies, Pisa); Franco Rabbia, Marco Pappaccogli and Silvia Di Monaco (AOU Città della Salute e della Scienza, Torino); Gian Paolo Rossi, Silvia Lerco, Angiola Bolis, Laura Zotta and Livia Lenzini (University Hospital, Padova); Pietro Minuz, Giancarlo Mansueto, Sergio De Marchi, Denise Marcon (Università di Verona, Verona).

*The Netherlands*: Daan J van Twist (Department of Internal Medicine, Zuyderland Medical Centre, Sittard/Heerlen), Bram Kroon and Peter de Leeuw (Maastricht University Medical Center, Maastricht); Wilko Spiering (University Medical Center Utrecht, Utrecht); Bert-Jan van den Born (Academic Medical Centre, University of Amsterdam, Amsterdam)

*Spain*: Juan Diego Mediavilla and Fernando Jaen Aguila (Virgen of The Nieves University Hospital, Granada, Spain); Nicolas Roberto Robles (Hospital Infanta Cristina, Badajoz); Esteban Poch, Enrique Montagud-Marrahi, Alicia Molina, Elena Guillen (Department of Nephrology and Kidney Transplantation, University of Barcelona, Barcelona) and Marta Burrel (Department of Radiology, Hospital Clinic, Barcelona)

*Switzerland*: Gregor Wuerzner (Service of Nephrology and Hypertension, Department of Medicine Lausanne University Hospital – CHUV, Lausanne); Lucia Mazzolai and Giacomo Buso (Division of Angiology, Heart and Vessel Department, Lausanne University Hospital - CHUV, Centre of rare vascular diseases and RAVAD registry, Lausanne).

*Tunisia*: Faiçal Jarraya and Hanen Chaker (Service de Néphrologie, CHU Hédi Chaker, Sfax, Tunisie)

**International stroke genetics consortium (ISGC) intracranial aneurysm working group**

Masato Akiyama

Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Department of Ocular Pathology and Imaging Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Varinder S. Alg

Stroke Research Centre, University College London, Institute of Neurology, London, UK

Marianne Bakke Johnsen

K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

Research and Communication Unit for Musculoskeletal Health (FORMI), Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Mark K. Bakker

Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands

Philippe Bijlenga

Neurosurgery Division, Department of Clinical Neurosciences, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Sigrid Børte

K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

Research and Communication Unit for Musculoskeletal Health (FORMI), Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Romain Bourcier

Université de Nantes, CHU Nantes, INSERM, CNRS, l'institut du thorax, Nantes, France.

CHU Nantes, Department of Neuroradiology, Nantes, France.

Joseph P. Broderick

University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Ben M. Brumpton

K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

Zhengming Chen

Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K.

Jerome Dauvillier

SIB Swiss Institute of Bioinformatics.

Hubert Desal

Université de Nantes, CHU Nantes, INSERM, CNRS, l'institut du thorax, Nantes, France.

CHU Nantes, Department of Neuroradiology, Nantes, France.

Christian Dina

Université de Nantes, CHU Nantes, INSERM, CNRS, l'institut du thorax, Nantes, France.

François Eugène

Department of Neuroradiology, University hospital of Rennes, Rennes, France.

Mikael von Und Zu Fraunberg

Neurosurgery NeuroCenter Kuopio University Hospital Kuopio Finland.

Institute of Clinical Medicine Faculty of Health Sciences University of Eastern Finland Kuopio Finland.

Christoph M. Friedrich

University of Applied Science and Arts, Dortmund.

Emília I. Gaál-Paavola

Department of Neurosurgery, Helsinki University Hospital, University of Helsinki, Finland.

Clinical Neurosciences, University of Helsinki, Topeliuksenkatu 5, 00260, Helsinki, Finland.

Jean-Christophe Gentric

Department of Neuroradiology, University hospital of Brest, Brest, France.

Sven Hirsch

Zurich University of Applied Sciences, School of Life Sciences and Facility Management.

Isabel C. Hostettler

Stroke Research Centre, University College London Queen Square Institute of Neurology, London, UK

Department of Neurosurgery, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.

Henry Houlden

Neurogenetics Laboratory, The National Hospital of Neurology and Neurosurgery, London, UK.

Kristian Hveem

K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

HUNT Research Center, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

Juha E. Jääskeläinen

Neurosurgery NeuroCenter Kuopio University Hospital Kuopio Finland.

Institute of Clinical Medicine Faculty of Health Sciences University of Eastern Finland Kuopio Finland.

Yoichiro Kamatani

Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Masaru Koido

Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Department of Cancer Biology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Liming Li

School of Public Health, Peking University Health Science Center, Beijing, China.

Kuang Lin

Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K.

Antti Lindgren

Neurosurgery NeuroCenter Kuopio University Hospital Kuopio Finland.

Institute of Clinical Medicine Faculty of Health Sciences University of Eastern Finland Kuopio Finland.

Olivier Martin

SIB Swiss Institute of Bioinformatics.

Koichi Matsuda

Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.

Iona Y. Millwood

Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K.

Medical Research Council Population Health Research Unit, University of Oxford, Oxford, U.K.

Sandrine Morel

Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Neurosurgery Division, Department of Clinical Neurosciences, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.

Olivier Naggara

Pediatric Radiology, Necker Hospital for Sick Children, Université Paris Descartes, Paris, France.

Department of Neuroradiology, Sainte-Anne Hospital and Université Paris Descartes, INSERM UMR S894, Paris, France.

Mika Niemelä

Department of Neurosurgery, Helsinki University Hospital, University of Helsinki, Finland.

Joanna Pera

Department of Neurology, Faculty of Medicine, Jagiellonian University Medical College, ul. Botaniczna 3, 31-503, Krakow, Poland.

Kristiina Rannikmäe

Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK.

Guy A. Rouleau

Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada.

Marie Søfteland Sandvei

Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

The Cancer Clinic, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.

Sabine Schilling

Zurich University of Applied Sciences, School of Life Sciences and Facility Management.

Eimad Shotar

Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France.

Agnieszka Slowik

Department of Neurology, Faculty of Medicine, Jagiellonian University Medical College, ul. Botaniczna 3, 31-503, Krakow, Poland.

Cathie L.M. Sudlow

Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK.

UK Biobank, Cheadle, Stockport, UK

Richard Redon

Université de Nantes, CHU Nantes, INSERM, CNRS, l'institut du thorax, Nantes, France.

Gabriel J.E. Rinkel

Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands

Ynte M. Ruigrok

Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands

Robin G. Walters

Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, U.K.

David J. Werring

Stroke Research Centre, University College London Queen Square Institute of Neurology, London, UK.

Cristen J. Willer

Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, 48109, MI, USA.

Bendik S. Winsvold

Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.

K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

Daniel Woo

University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Bradford B. Worrall

Departments of Neurology and Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA.

Sirui Zhou

Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, QC, Canada.

John-Anker Zwart

Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.

K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.

Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

**MEGASTROKE CONSORTIUM**

Rainer Malik 1, Ganesh Chauhan 2, Matthew Traylor 3, Muralidharan Sargurupremraj 4,5, Yukinori Okada 6,7,8, Aniket Mishra 4,5, Loes Rutten-Jacobs 3, Anne-Katrin Giese 9, Sander W van der Laan 10, Solveig Gretarsdottir 11, Christopher D Anderson 12,13,14,14, Michael Chong 15, Hieab HH Adams 16,17, Tetsuro Ago 18, Peter Almgren 19, Philippe Amouyel 20,21, Hakan Ay 22,13, Traci M Bartz 23, Oscar R Benavente 24, Steve Bevan 25, Giorgio B Boncoraglio 26, Robert D Brown, Jr.  27, Adam S Butterworth 28,29, Caty Carrera 30,31, Cara L Carty 32,33, Daniel I Chasman 34,35, Wei-Min Chen 36, John W Cole 37, Adolfo Correa 38, Ioana Cotlarciuc 39, Carlos Cruchaga 40,41, John Danesh 28,42,43,44, Paul IW de Bakker 45,46, Anita L DeStefano 47,48, Marcel den Hoed 49, Qing Duan 50, Stefan T Engelter 51,52, Guido J Falcone 53,54, Rebecca F Gottesman 55, Raji P Grewal 56, Vilmundur Gudnason 57,58, Stefan Gustafsson 59, Jeffrey Haessler 60, Tamara B Harris 61, Ahamad Hassan 62, Aki S Havulinna 63,64, Susan R Heckbert 65, Elizabeth G Holliday 66,67, George Howard 68, Fang-Chi Hsu 69, Hyacinth I Hyacinth 70, M Arfan Ikram 16, Erik Ingelsson 71,72, Marguerite R Irvin 73, Xueqiu Jian 74, Jordi Jiménez-Conde 75, Julie A Johnson 76,77, J Wouter Jukema 78, Masahiro Kanai 6,7,79, Keith L Keene 80,81, Brett M Kissela 82, Dawn O Kleindorfer 82, Charles Kooperberg 60, Michiaki Kubo 83, Leslie A Lange 84, Carl D Langefeld 85, Claudia Langenberg 86, Lenore J Launer 87, Jin-Moo Lee 88, Robin Lemmens 89,90, Didier Leys 91, Cathryn M Lewis 92,93, Wei-Yu Lin 28,94, Arne G Lindgren 95,96, Erik Lorentzen 97, Patrik K Magnusson 98, Jane Maguire 99, Ani Manichaikul 36, Patrick F McArdle 100, James F Meschia 101, Braxton D Mitchell 100,102, Thomas H Mosley 103,104, Michael A Nalls 105,106, Toshiharu Ninomiya 107, Martin J O'Donnell 15,108, Bruce M Psaty 109,110,111,112, Sara L Pulit 113,45, Kristiina Rannikmäe 114,115, Alexander P Reiner 65,116, Kathryn M Rexrode 117, Kenneth Rice 118, Stephen S Rich 36, Paul M Ridker 34,35, Natalia S Rost 9,13, Peter M Rothwell 119, Jerome I Rotter 120,121, Tatjana Rundek 122, Ralph L Sacco 122, Saori Sakaue 7,123, Michele M Sale 124, Veikko Salomaa 63, Bishwa R Sapkota 125, Reinhold Schmidt 126, Carsten O Schmidt  127, Ulf Schminke 128, Pankaj Sharma 39, Agnieszka Slowik 129, Cathie LM Sudlow 114,115, Christian Tanislav 130, Turgut Tatlisumak 131,132, Kent D Taylor 120,121, Vincent NS Thijs 133,134, Gudmar Thorleifsson 11, Unnur Thorsteinsdottir 11, Steffen Tiedt 1, Stella Trompet 135, Christophe Tzourio 5,136,137, Cornelia M van Duijn 138,139, Matthew Walters 140, Nicholas J Wareham 86, Sylvia Wassertheil-Smoller 141, James G Wilson 142, Kerri L Wiggins 109, Qiong Yang 47, Salim Yusuf 15, Najaf Amin 16, Hugo S Aparicio 185,48, Donna K Arnett 186, John Attia 187, Alexa S Beiser 47,48, Claudine Berr 188, Julie E Buring 34,35, Mariana Bustamante 189, Valeria Caso 190, Yu-Ching Cheng 191, Seung Hoan Choi 192,48, Ayesha Chowhan 185,48, Natalia Cullell 31, Jean-François Dartigues 193,194, Hossein Delavaran 95,96, Pilar Delgado 195, Marcus Dörr 196,197, Gunnar Engström 19, Ian Ford 198, Wander S Gurpreet 199, Anders Hamsten 200,201, Laura Heitsch 202, Atsushi Hozawa 203, Laura Ibanez 204, Andreea Ilinca 95,96, Martin Ingelsson 205, Motoki Iwasaki 206, Rebecca D Jackson 207, Katarina Jood 208, Pekka Jousilahti 63, Sara Kaffashian 4,5, Lalit Kalra 209, Masahiro Kamouchi 210, Takanari Kitazono 211, Olafur Kjartansson 212, Manja Kloss 213, Peter J Koudstaal 214, Jerzy Krupinski 215, Daniel L Labovitz 216, Cathy C Laurie 118, Christopher R Levi 217, Linxin Li 218, Lars Lind 219, Cecilia M Lindgren 220,221, Vasileios Lioutas 222,48, Yong Mei Liu 223, Oscar L Lopez 224, Hirata Makoto 225, Nicolas Martinez-Majander 172, Koichi Matsuda 225, Naoko Minegishi 203, Joan Montaner  226, Andrew P Morris 227,228, Elena Muiño 31, Martina Müller-Nurasyid 229,230,231, Bo Norrving 95,96, Soichi Ogishima 203, Eugenio A Parati 232, Leema Reddy Peddareddygari 56, Nancy L Pedersen 98,233, Joanna Pera 129, Markus Perola 63,234, Alessandro Pezzini 235, Silvana Pileggi 236, Raquel Rabionet 237, Iolanda Riba-Llena 30, Marta Ribasés 238, Jose R Romero 185,48, Jaume Roquer 239,240, Anthony G Rudd 241,242, Antti-Pekka Sarin 243,244, Ralhan Sarju 199, Chloe Sarnowski 47,48, Makoto Sasaki 245, Claudia L Satizabal 185,48, Mamoru Satoh 245, Naveed Sattar 246, Norie Sawada 206, Gerli Sibolt 172, Ásgeir Sigurdsson 247, Albert Smith 248, Kenji Sobue 245, Carolina Soriano-Tárraga 240, Tara Stanne 249, O Colin Stine 250, David J Stott 251, Konstantin Strauch 229,252, Takako Takai  203, Hideo Tanaka 253,254, Kozo Tanno 245, Alexander Teumer 255, Liisa Tomppo 172, Nuria P Torres-Aguila 31, Emmanuel Touze 256,257, Shoichiro Tsugane  206, Andre G Uitterlinden 258, Einar M Valdimarsson 259, Sven J van der Lee 16, Henry Völzke 255, Kenji Wakai  253, David Weir 260, Stephen R Williams 261, Charles DA Wolfe 241,242, Quenna Wong 118, Huichun Xu 191, Taiki Yamaji 206, Dharambir K Sanghera 125,169,170, Olle Melander 19, Christina Jern 171, Daniel Strbian 172,173, Israel Fernandez-Cadenas 31,30, W T Longstreth, Jr 174,65, Arndt Rolfs 175, Jun Hata 107, Daniel Woo 82, Jonathan Rosand 12,13,14, Guillaume Pare 15, Jemma C Hopewell 176, Danish Saleheen 177, Kari Stefansson 11,178, Bradford B Worrall 179, Steven J Kittner 37, Sudha Seshadri 180,48, Myriam Fornage 74,181, Hugh S Markus 3, Joanna MM Howson 28, Yoichiro Kamatani 6,182, Stephanie Debette 4,5, Martin Dichgans 1,183,184

1 Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

2 Centre for Brain Research, Indian Institute of Science, Bangalore, India

3 Stroke Research Group, Division of Clinical Neurosciences, University of Cambridge, UK

4 INSERM U1219 Bordeaux Population Health Research Center, Bordeaux, France

5 University of Bordeaux, Bordeaux, France

6 Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

7 Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan

8 Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan.

9 Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

10 Laboratory of Experimental Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, University of Utrecht, Utrecht,Netherlands

11 deCODE genetics/AMGEN inc, Reykjavik, Iceland

12 Center for Genomic Medicine, Massachusetts General Hospital (MGH), Boston, MA, USA

13 J. Philip Kistler Stroke Research Center, Department of Neurology, MGH, Boston, MA, USA

14 Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA

15 Population Health Research Institute, McMaster University, Hamilton, Canada

16 Department of Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands

17 Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, Netherlands

18 Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

19 Department of Clinical Sciences, Lund University, Malmö, Sweden

20 Univ. Lille, Inserm, Institut Pasteur de Lille, LabEx DISTALZ-UMR1167, Risk factors and molecular determinants of aging-related diseases, F-59000 Lille, France

21 Centre Hosp. Univ Lille, Epidemiology and Public Health Department, F-59000 Lille, France

22 AA Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

23 Cardiovascular Health Research Unit, Departments of Biostatistics and Medicine, University of Washington, Seattle, WA, USA

24 Division of Neurology, Faculty of Medicine, Brain Research Center, University of British Columbia, Vancouver, Canada

25 School of Life Science, University of Lincoln, Lincoln, UK

26 Department of Cerebrovascular Diseases, Fondazione IRCCS Istituto Neurologico "Carlo Besta", Milano, Italy

27 Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA

28 MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

29 The National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, UK

30 Neurovascular Research Laboratory, Vall d'Hebron Institut of Research, Neurology and Medicine Departments-Universitat Autònoma de Barcelona, Vall d’Hebrón Hospital, Barcelona, Spain

31 Stroke Pharmacogenomics and Genetics, Fundacio Docència i Recerca MutuaTerrassa, Terrassa, Spain

32 Children's Research Institute, Children's National Medical Center, Washington, DC, USA

33 Center for Translational Science, George Washington University, Washington, DC, USA

34 Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA

35 Harvard Medical School, Boston, MA, USA

36 Center for Public Health Genomics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA

37 Department of Neurology, University of Maryland School of Medicine and Baltimore VAMC, Baltimore, MD, USA

38 Departments of Medicine, Pediatrics and Population Health Science, University of Mississippi Medical Center, Jackson, MS, USA

39 Institute of Cardiovascular Research, Royal Holloway University of London, UK  &  Ashford and St Peters Hospital, Surrey UK

40 Department of Psychiatry,The Hope Center Program on Protein Aggregation and Neurodegeneration (HPAN),Washington University, School of Medicine, St. Louis, MO, USA

41 Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO, USA

42 NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

43 Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,  Cambridge, UK

44 British Heart Foundation, Cambridge Centre of Excellence, Department of Medicine, University of Cambridge, Cambridge, UK

45 Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands

46 Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands

47 Boston University School of Public Health, Boston, MA, USA

48 Framingham Heart Study, Framingham, MA, USA

49 Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden

50 Department of Genetics, University of North Carolina, Chapel Hill, NC, USA

51 Department of Neurology and Stroke Center, Basel University Hospital, Switzerland

52 Neurorehabilitation Unit, University and University Center for Medicine of Aging and Rehabilitation Basel, Felix Platter Hospital, Basel, Switzerland

53 Department of Neurology, Yale University School of Medicine, New Haven, CT, USA

54 Program in Medical and Population Genetics, The Broad Institute of Harvard and MIT, Cambridge, MA, USA

55 Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

56 Neuroscience Institute, SF Medical Center, Trenton, NJ, USA

57 Icelandic Heart Association Research Institute, Kopavogur, Iceland

58 University of Iceland, Faculty of Medicine, Reykjavik, Iceland

59 Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden

60 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

61 Laboratory of Epidemiology and Population Science, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

62 Department of Neurology, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds, UK

63 National Institute for Health and Welfare, Helsinki, Finland

64 FIMM - Institute for Molecular Medicine Finland, Helsinki, Finland

65 Department of Epidemiology, University of Washington, Seattle, WA, USA

66 Public Health Stream, Hunter Medical Research Institute, New Lambton, Australia

67 Faculty of Health and Medicine, University of Newcastle, Newcastle, Australia

68 School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA

69 Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA

70 Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA

71 Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, CA, USA

72 Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden

73 Epidemiology, School of Public Health, University of Alabama at Birmingham, USA

74 Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA

75 Neurovascular Research Group (NEUVAS), Neurology Department, Institut Hospital del Mar d'Investigació Mèdica, Universitat Autònoma de Barcelona, Barcelona, Spain

76 Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, College of Pharmacy, Gainesville, FL, USA

77 Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL, USA

78 Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands

79 Program in Bioinformatics and Integrative Genomics, Harvard Medical School, Boston, MA, USA

80 Department of Biology, East Carolina University, Greenville, NC, USA

81 Center for Health Disparities, East Carolina University, Greenville, NC, USA

82 University of Cincinnati College of Medicine, Cincinnati, OH, USA

83 RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

84 Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA

85 Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA

86 MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK

87 Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

88 Department of Neurology, Radiology, and Biomedical Engineering, Washington University School of Medicine, St. Louis, MO, USA

89 KU Leuven – University of Leuven, Department of Neurosciences,  Experimental Neurology, Leuven, Belgium

90 VIB Center for Brain & Disease Research, University Hospitals Leuven, Department of Neurology, Leuven, Belgium

91 Univ.-Lille, INSERM U 1171. CHU Lille. Lille, France

92 Department of Medical and Molecular Genetics, King's College London, London, UK

93 SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

94 Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Newcastle, UK

95 Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden

96 Department of Neurology and Rehabilitation Medicine, Skåne University Hospital, Lund, Sweden

97 Bioinformatics Core Facility, University of Gothenburg, Gothenburg, Sweden

98 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

99 University of Technology Sydney, Faculty of Health, Ultimo, Australia

100 Department of Medicine, University of Maryland School of Medicine, MD, USA

101 Department of Neurology, Mayo Clinic, Jacksonville, FL, USA

102 Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, MD, USA

103 Division of Geriatrics, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA

104 Memory Impairment and Neurodegenerative Dementia Center, University of Mississippi Medical Center, Jackson, MS, USA

105 Laboratory of Neurogenetics, National Institute on Aging, National institutes of Health, Bethesda, MD, USA

106 Data Tecnica International, Glen Echo MD, USA

107 Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

108 Clinical Research Facility, Department of Medicine, NUI Galway, Galway, Ireland

109 Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA

110 Department of Epidemiology, University of Washington, Seattle, WA

111 Department of Health Services, University of Washington, Seattle, WA, USA

112 Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA

113 Brain Center Rudolf Magnus, Department of Neurology, University Medical Center Utrecht, Utrecht, The Netherlands

114 Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK

115 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

116 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA

117 Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

118 Department of Biostatistics, University of Washington, Seattle, WA, USA

119 Nuffield Department of Clinical Neurosciences, University of Oxford, UK

120 Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at  Harbor-UCLA Medical Center, Torrance, CA, USA

121 Division of Genomic Outcomes, Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA

122 Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA

123 Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan

124 Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA

125 Department of Pediatrics, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

126 Department of Neurology, Medical University of Graz, Graz, Austria

127 University Medicine  Greifswald, Institute for Community Medicine, SHIP-KEF, Greifswald, Germany

128 University Medicine  Greifswald,  Department of Neurology, Greifswald, Germany

129 Department of Neurology, Jagiellonian University, Krakow, Poland

130 Department of Neurology, Justus Liebig University, Giessen, Germany

131 Department of Clinical Neurosciences/Neurology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

132 Sahlgrenska University Hospital, Gothenburg, Sweden

133 Stroke Division, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Australia

134 Austin Health, Department of Neurology, Heidelberg, Australia

135 Department of Internal Medicine, Section Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands

136 INSERM U1219, Bordeaux, France

137 Department of Public Health, Bordeaux University Hospital, Bordeaux, France

138 Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center Rotterdam, Netherlands

139 Center for Medical Systems Biology, Leiden, Netherlands

140 School of Medicine, Dentistry and Nursing at the University of Glasgow, Glasgow, UK

141 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, NY, USA

142 Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA

143 A full list of members and affiliations appears in the Supplementary Note

144 Department of Human Genetics, McGill University, Montreal, Canada

145 Department of Pathophysiology, Institute of Biomedicine and Translation Medicine, University of Tartu, Tartu, Estonia

146 Department of Cardiac Surgery, Tartu University Hospital, Tartu, Estonia

147 Clinical Gene Networks AB,Stockholm, Sweden

148 Department of Genetics and Genomic Sciences, The Icahn Institute for Genomics and Multiscale Biology Icahn School of Medicine at Mount Sinai, New York, NY , USA

149 Department of Pathophysiology, Institute of Biomedicine and Translation Medicine, University of Tartu, Biomeedikum, Tartu, Estonia

150 Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden.

151 Clinical Gene Networks AB, Stockholm, Sweden

152 Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR\_S 1166, Team Genomics & Pathophysiology of Cardiovascular Diseases, Paris, France

153 ICAN Institute for Cardiometabolism and Nutrition, Paris, France

154 Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA

155 Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA

156 Seattle Epidemiologic Research and Information Center, VA Office of Research and Development, Seattle, WA, USA

157 Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA

158 Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway

159 Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore

160 National Heart and Lung Institute, Imperial College London, London, UK

161 Department of Gene Diagnostics and Therapeutics, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan

162 Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA

163 Department of Cardiology,University Medical Center Groningen, University of Groningen, Netherlands

164 MRC-PHE Centre for Environment and Health, School of Public Health, Department of Epidemiology and Biostatistics, Imperial College London, London, UK

165 Department of Epidemiology and Biostatistics, Imperial College London, London, UK

166 Department of Cardiology, Ealing Hospital NHS Trust, Southall, UK

167 National Heart, Lung and Blood Research Institute, Division of Intramural Research, Population Sciences Branch, Framingham, MA, USA

168 A full list of members and affiliations appears at the end of the manuscript

169 Department of Phamaceutical Sciences, Collge of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

170 Oklahoma Center for Neuroscience, Oklahoma City, OK, USA

171 Department of Pathology and Genetics, Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

172 Department of Neurology, Helsinki University Hospital, Helsinki, Finland

173 Clinical Neurosciences, Neurology, University of Helsinki, Helsinki, Finland

174 Department of Neurology, University of Washington, Seattle, WA, USA

175 Albrecht Kossel Institute, University Clinic of Rostock, Rostock, Germany

176 Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

177 Department of Genetics, Perelman School of Medicine, University of Pennsylvania, PA, USA

178 Faculty of Medicine, University of Iceland, Reykjavik, Iceland

179 Departments of Neurology and Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA

180 Department of Neurology, Boston University School of Medicine, Boston, MA, USA

181 Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA

182 Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

183 Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

184 German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

185 Boston University School of Medicine, Boston, MA, USA

186 University of Kentucky College of Public Health, Lexington, KY, USA

187 University of Newcastle and Hunter Medical Research Institute, New Lambton, Australia

188 Univ. Montpellier, Inserm, U1061, Montpellier, France

189 Centre for Research in Environmental Epidemiology, Barcelona, Spain

190 Department of Neurology, Università degli Studi di Perugia, Umbria, Italy

191 Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

192 Broad Institute, Cambridge, MA, USA

193 Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France

194 Bordeaux University Hospital, Department of Neurology, Memory Clinic, Bordeaux, France

195 Neurovascular Research Laboratory. Vall d'Hebron Institut of Research, Neurology and Medicine Departments-Universitat Autònoma de Barcelona. Vall d’Hebrón Hospital, Barcelona, Spain

196 University Medicine Greifswald, Department of Internal Medicine B, Greifswald, Germany

197 DZHK, Greifswald, Germany

198 Robertson Center for Biostatistics, University of Glasgow, Glasgow, UK

199 Hero DMC Heart Institute, Dayanand Medical College & Hospital, Ludhiana, India

200 Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

201 Karolinska Institutet, Stockholm, Sweden

202 Division of Emergency Medicine, and Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA

203 Tohoku Medical Megabank Organization, Sendai, Japan

204 Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA

205 Department of Public Health and Caring Sciences / Geriatrics, Uppsala University, Uppsala, Sweden

206 Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan

207 Department of Internal Medicine and the Center for Clinical and Translational Science, The Ohio State University, Columbus, OH, USA

208 Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Goteborg, Sweden

209 Department of Basic and Clinical Neurosciences, King's College London, London, UK

210 Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Japan

211 Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan

212 Landspitali National University Hospital, Departments of Neurology & Radiology, Reykjavik, Iceland

213 Department of Neurology, Heidelberg University Hospital, Germany

214 Department of Neurology, Erasmus University Medical Center

215 Hospital Universitari Mutua Terrassa, Terrassa (Barcelona), Spain

216 Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY, USA

217 John Hunter Hospital, Hunter Medical Research Institute and University of Newcastle, Newcastle, NSW, Australia

218 Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, UK

219 Department of Medical Sciences, Uppsala University, Uppsala, Sweden

220 Genetic and Genomic Epidemiology Unit, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK

221 The Wellcome Trust Centre for Human Genetics, Oxford, UK

222 Beth Israel Deaconess Medical Center, Boston, MA, USA

223 Wake Forest School of Medicine, Wake Forest, NC, USA

224 Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA

225 BioBank Japan, Laboratory of Clinical Sequencing, Department of Computational biology and medical Sciences, Graduate school of Frontier Sciences, The University of Tokyo, Tokyo, Japan

226 Neurovascular Research Laboratory, Vall d'Hebron Institut of Research, Neurology and Medicine Departments-Universitat Autònoma de Barcelona. Vall d’Hebrón Hospital, Barcelona, Spain

227 Department of Biostatistics, University of Liverpool, Liverpool, UK

228 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK

229 Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany

230 Department of Medicine I, Ludwig-Maximilians-Universität, Munich, Germany

231 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany

232 Department of Cerebrovascular Diseases, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milano, Italy

233 Karolinska Institutet, MEB, Stockholm, Sweden

234 University of Tartu, Estonian Genome Center, Tartu, Estonia, Tartu, Estonia

235 Department of Clinical and Experimental Sciences, Neurology Clinic, University of Brescia, Italy

236 Translational Genomics Unit, Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy

237 Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain

238 Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addictions, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain

239 Department of Neurology, IMIM-Hospital del Mar, and Universitat Autònoma de Barcelona, Spain

240 IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

241 National Institute for Health Research Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust and King's College London, London, UK

242 Division of Health and Social Care Research, King's College London, London, UK

243 FIMM-Institute for Molecular Medicine Finland, Helsinki, Finland

244 THL-National Institute for Health and Welfare, Helsinki, Finland

245 Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, Japan

246 BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, Glasgow, UK

247 deCODE Genetics/Amgen, Inc., Reykjavik, Iceland

248 Icelandic Heart Association, Reykjavik, Iceland

249 Institute of Biomedicine, the Sahlgrenska Academy at University of Gothenburg, Goteborg, Sweden

250 Department of Epidemiology, University of Maryland School of Medicine, Baltimore, MD, USA

251 Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, Glasgow, UK

252 Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Germany

253 Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan

254 Department of Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan

255 University Medicine Greifswald, Institute for Community Medicine, SHIP-KEF, Greifswald, Germany

256 Department of Neurology, Caen University Hospital, Caen, France

257 University of Caen Normandy, Caen, France

258 Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands

259 Landspitali University Hospital, Reykjavik, Iceland

260 Survey Research Center, University of Michigan, Ann Arbor, MI, USA

261 University of Virginia Department of Neurology, Charlottesville, VA, USA